logo
welcome
Benzinga

Benzinga

Sangamo Therapeutics, Inc. (SGMO) regains development and commercialization rights to giroctocogene fitelparvovec

Benzinga
Summary
Nutrition label

74% Informative

Sangamo Therapeutics, Inc. (NASDAQ: SGMO ) regained the development and commercialization rights to giroctocogene fitelparvovec.

Pfizer decided to terminate the global collaboration and license agreement between the parties.

Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner.

VR Score

66

Informative language

63

Neutral language

30

Article tone

formal

Language

English

Language complexity

75

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links